Together, these results demonstrate key differences in how RAS wild-type normal tissues react and adapt to metronomic RAS inhibition with a broad-spectrum RAS inhibitor compared with tumours driven by mutant KRAS, providing a rational basis for the tumour selectivity of RAS inhibition in PDAC. The gene discussed is KRAS; the disease is neoplasm.